Elsevier

Vaccine

Volume 23, Issue 5, 16 December 2004, Pages 646-655
Vaccine

Bovine respiratory syncytial virus ISCOMs—protection in the presence of maternal antibodies

https://doi.org/10.1016/j.vaccine.2004.07.006Get rights and content

Abstract

The protection induced by immunostimulating complexes (ISCOMs) against bovine respiratory syncytial virus (BRSV) was evaluated and compared to that of a commercial inactivated vaccine (CV) in calves with BRSV-specific maternal antibodies. Following experimental challenge, controls (n = 4) and animals immunized with CV (n = 5) developed moderate to severe respiratory disease, whereas calves immunized with ISCOMs (n = 5) remained clinically healthy. BRSV was re-isolated from the nasopharynx of all controls and from all calves immunized with CV, but from none of the calves immunized with ISCOMs. BRSV-RNA was detected by real-time PCR from a single animal in this group. Significantly higher BRSV-specific nasal IgG, serum IgG1 and IgG2 titers were detected before and after challenge in animals immunized with ISCOMs versus CV. In conclusion, the ISCOMs overcame the suppressive effect of maternal antibodies in calves and induced strong clinical and virological protection against a BRSV challenge.

Introduction

Bovine respiratory syncytial virus (BRSV), a Pneumovirus in the Paramyxoviridae family, is a common agent of respiratory disease in cattle [1] and an important threat to animal welfare. Animal losses, treatment costs and decreased production cause economic losses to the industry and there is a great need for effective prophylactic measures directed against infections [2], [3], [4]. BRSV commonly infects young individuals and disease occurs even in the presence of maternal antibodies [5]. Bearing in mind that the seroprevalence to BRSV is high in most countries [4], [6], ideally vaccines should be effective at an early age and be able to overcome the immunosuppressive effects of maternal antibodies.

Both live and inactivated BRSV vaccines are available on the European and North American market and both are associated with different advantages and disadvantages. Whereas parenterally administered live vaccines are immunogenic [7], [8], vaccination in the presence of a natural infection may result in enhanced disease [9] and humoral immune responses are suppressed by maternal antibody [7]. Moreover, there is a risk for contamination of live vaccines with pathogens, such as bovine viral diarrhea virus (BVDV) [10], [11]. Inactivated vaccines on the other hand, have in a few cases been reported to cause exacerbated disease upon a subsequent BRSV infection [12], [13], [14] and have repeatedly provided unsatisfactory protection against clinical disease in calves with maternal antibodies [13], [15], [16]. Nevertheless, one inactivated vaccine based on glutaraldehyde-fixed bovine nasal cells persistently infected with BRSV and with Quillaja saponin as adjuvant has been reported to reduce clinical disease in the field [17]. Furthermore, this vaccine significantly reduced virus shedding following experimental BRSV challenge, even in calves with high levels of maternal antibodies at the time of vaccination [10], [18].

Because of the difficulties in experimentally reproducing respiratory disease in calves with passively derived antibodies [19], [20], BRSV vaccines are commonly evaluated in seronegative calves [8], [21], [22], [23], [24], [25], [26], [27]. Recently, however, the bovine RSV infection model has been improved. The use of low passage isolates, grown in lung cells from the host species and administered into calves by aerosol, has made it possible to induce severe signs of respiratory disease with low doses of virus even in seropositive calves [28]. Hence, we now have the possibility to evaluate protection induced by BRSV vaccines against severe disease in conventionally reared calves. Since BRSV infections in cattle closely resemble human RSV (HRSV) infections in man, results achieved in experiments on calves with maternal antibodies will also provide information about vaccination strategies against HRSV in children.

In search of a new BRSV vaccine candidate, the bovine model was used to evaluate the efficacy of BRSV immunostimulating complexes (ISCOMs) in calves with maternal antibodies. BRSV envelope proteins were incorporated into spherical particles with inbuilt adjuvant, ISCOMs, and administered to calves subcutaneously. In addition to unimmunized controls, a group of calves immunized with a commercial inactivated vaccine (CV) against BRSV was included in the experiment. In this paper, we show that ISCOMs, in contrast to the CV, provided protection against clinical disease in calves and also significantly reduced virus shedding following BRSV challenge.

Section snippets

Cells

Foetal bovine turbinate (FBT, National Veterinary Institute, Sweden) cells and Foetal Bovine Lung (FBL, Danish Veterinary Laboratory, Denmark) cells at low passages were grown in full Dulbecco's modified Eagle medium (F-DMEM, National Veterinary Institute, Sweden), supplemented with 10 ml 2 mM glutamine, 100 mg kanamycin, and 20 ml gamma-irradiated foetal bovine serum (GibcoBRL, Life Technologies AB, Sweden) per litre (F-DMEM+).

Virus for ISCOMs

A BRSV isolate (Weybridge Hud 5), provided by Dr. M. Merza (Svanova

Clinical signs

No adverse clinical reactions were observed after first or second immunization. Following BRSV challenge, moderate (clinical score ≥4 on 3 days or more) to severe (clinical score ≥10 on 1 day or more) respiratory disease was recorded in all four unvaccinated controls from day 5 (for mean clinical scores, see Fig. 1). Two calves in this group (nos. 20 and 27) that showed pronounced abdominal breathing were, for humane reasons, euthanized on day 6. BRSV infections of these calves were confirmed

Discussion

Since first described by Morein et al. [42], a multitude of studies on ISCOMs have highlighted their ability to induce strong and durable immune responses to a variety of pathogens [43], [44]. ISCOMs incorporating BRSV have elicited neutralizing responses in guinea pig, equivalent to those of a live vaccine [45]. In view of the fact that BRSV disease often occurs in young animals [5] and that immunization is likely to be carried out in herds where the virus is circulating [9], the present

Acknowledgements

This work was funded by the European Union ‘Neovac’ Consortium, The Swedish farmers foundation (grant 343/02) and the National Veterinary Institute, Sweden (grant 60223). We wish to thank Mrs. M. Hjort, Mr. I. Larsen, and Mrs. S. Wyld for performing ELISA assays and Mr. B. Norén with staff for rearing and maintenance of experimental animals. Dr. K. Tjornehoj and Dr. U. Power are thanked for generous advices and ideas regarding the experimental BRSV challenge, Dr. P. Öhagen for help with

References (54)

  • A.L. Lindberg et al.

    Principles for eradication of bovine viral diarrhoea virus (BVDV) infections in cattle populations

    Vet Microbiol

    (1999)
  • A. Uttenthal et al.

    Antibody dynamics in BRSV-infected Danish dairy herds as determined by isotype-specific immunoglobulins

    Vet Microbiol

    (2000)
  • M. Traven et al.

    Experimental reproduction of winter dysentery in lactating cows using BCV—comparison with BCV infection in milk-fed calves

    Vet Microbiol

    (2001)
  • T.G. Kimman et al.

    Isotype-specific ELISAs for the detection of antibodies to bovine respiratory syncytial virus

    Res Vet Sci

    (1987)
  • L.H. Thomas et al.

    A search for new microorganisms in calf pneumonia by the inoculation of gnotobiotic calves

    Res Vet Sci

    (1982)
  • B. Morein et al.

    Immunomodulation by iscoms, immune stimulating complexes

    Methods

    (1999)
  • M. Trudel et al.

    Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus

    Vaccine

    (1989)
  • W.M. Sullender et al.

    Mutations of respiratory syncytial virus attachment glycoprotein G associated with resistance to neutralization by primate polyclonal antibodies

    Virology

    (1999)
  • L.E. Larsen et al.

    Serological and genetic characterisation of bovine respiratory syncytial virus (BRSV) indicates that Danish isolates belong to the intermediate subgroup: no evidence of a selective effect on the variability of G protein nucleotide sequence by prior cell culture adaption and passages in cell culture or calves

    Vet Microbiol

    (1998)
  • E.J. Stott et al.

    A survey of virus infections of the respiratory tract of cattle and their association with disease

    J Hyg (Lond)

    (1980)
  • M. Elvander

    Severe respiratory disease in dairy cows caused by infection with bovine respiratory syncytial virus

    Vet Rec

    (1996)
  • T.G. Kimman et al.

    Epidemiological study of bovine respiratory syncytial virus infections in calves: influence of maternal antibodies on the outcome of disease

    Vet Rec

    (1988)
  • D.J. Paton et al.

    Prevalence of antibodies to bovine virus diarrhoea virus and other viruses in bulk tank milk in England and Wales

    Vet Rec

    (1998)
  • T.G. Kimman et al.

    A severe outbreak of respiratory tract disease associated with bovine respiratory syncytial virus probably enhanced by vaccination with modified live vaccine

    Vet Q

    (1989)
  • E.J. Stott et al.

    A comparison of three vaccines against respiratory syncytial virus in calves

    J Hyg (Lond)

    (1984)
  • H.W. Barkema et al.

    Outbreak of bovine virus diarrhea on Dutch dairy farms induced by a bovine herpesvirus 1 marker vaccine contaminated with bovine virus diarrhea virus type 2

    Tijdschr Diergeneeskd

    (2001)
  • P. Schreiber et al.

    High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian white blue calves previously vaccinated with an inactivated BRSV vaccine

    J Vet Med B Infect Dis Vet Public Health

    (2000)
  • Cited by (46)

    • Nasal nanovaccines

      2017, International Journal of Pharmaceutics
      Citation Excerpt :

      Concerning larger animal models, mucosal IgA production was stimulated in Merino ewes after intranasal administration of ISCOMs (Coulter et al., 2003). Hägglund and co-workers intranasally vaccinated calves with ISCOMs, eliciting strong protection against bovine respiratory syncytial virus (Hagglund et al., 2004). A virosomal H5N1 influenza vaccine with ISCOMatrix™ as an adjuvant reached phase I clinical trials, but while this vaccine is efficient in triggering specific-IgG, it is administered through intramuscular injection (Pedersen et al., 2014).

    • Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis

      2017, The Lancet Infectious Diseases
      Citation Excerpt :

      Furthermore, maternal antibodies provide partial protection against the incidence and severity of disease in calves.150,151 Evidence suggests that following vaccination or natural infection in calves, maternal antibody can interfere with development of immunity to respiratory syncytial virus,152–154 although some vaccine formulations might overcome this suppressive effect.155,156 In cotton rats, evidence indicates that high titres of antibody can interfere with vaccination against respiratory syncytial virus in pups and adults.157,158

    • Respiratory Virus Vaccines

      2015, Mucosal Immunology: Fourth Edition
    • Alternative vaccine delivery methods

      2012, Vaccines: Sixth Edition
    • Bovine respiratory syncytial virus ISCOMs-Immunity, protection and safety in young conventional calves

      2011, Vaccine
      Citation Excerpt :

      The adverse reactions in the BRSV-ISCOM and adjuvant group upon boosting were of similar extent as can be observed with commercial cattle vaccines. These reactions were probably linked to the Quillaja saponin component that was increased from 5 to 13 times that of the lipids and proteins compared to previously [27]. Besides not causing direct toxicity and acute hypersensitivity reactions, BRSV vaccines must not induce exaggerated inflammatory responses upon natural infection.

    View all citing articles on Scopus
    View full text